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cancer in association with use of metformin or
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Abstract
Background: Use of metformin has been associated with a decreased cancer risk. We aimed to explore whether
use of metformin or other antidiabetic drugs is associated with a decreased risk for thyroid cancer.
Methods: We conducted a case-control analysis (1995 to 2014) using the U.K.-based Clinical Practice Research
Datalink (CPRD). Cases had a first-time diagnosis of thyroid cancer, six controls per case were matched on age, sex,
calendar time, general practice, and number of years of active history in the database prior to the index date. We
assessed odds ratios (ORs) with 95 % confidence intervals (95 % CI), adjusted for body mass index (BMI), smoking,
and diabetes mellitus.
Results: In 1229 cases and 7374 matched controls, the risk of thyroid cancer associated with ever use of metformin
yielded an adjusted OR of 1.48, 95 % CI 0.86–2.54. The relative risk estimate was highest in long-term (≥30
prescriptions) users of metformin (adjusted OR 1.83, 95 % CI 0.92–3.65), based on a limited number of 26 exposed
cases. No such association was found in users of sulfonylurea, insulin, or thiazolidinediones (TZD). Neither a diabetes
diagnosis (adjusted OR 1.17, 95 % CI 0.89–1.54), nor diabetes duration >8 years (adjusted OR 1.22, 95 % CI 0.60–2.51)
altered the risk of thyroid cancer.
Conclusion: In our observational study with limited statistical power, neither use of metformin nor of other
antidiabetic drugs were associated with a decreased risk of thyroid cancer.
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Background
Thyroid cancer is by far the most common malignant
endocrine tumor but accounts for only 2 % of all malig-
nant neoplasms in the U.S. [1]. Thyroid carcinomas are
mostly from the differentiated type (95 %) while anaplas-
tic types are rare [2]. Women are three times more often
affected than men [2]. The overall incidence of thyroid
cancer has risen in recent years both in men and women
and across different countries [1, 2]. This increasing inci-
dence is only partially explained by earlier detection of
subclinical disease and by increased sensitivity of diag-
nostic tests, since the incidence of tumors of all sizes
has risen in recent years [1–3].
Risk factors for thyroid cancer include exposure to ra-
diation in childhood [4] and rare genetic causes such as
a family history of the thyroid cancer syndrome [5]. Data
from observational studies suggest that benign thyroid
disease [6, 7], hyperthyroidism [8], refraining from
smoking and alcohol consumption [9], and high body
mass index (BMI) [10] may be associated with an in-
creased risk of thyroid cancer. Diabetes mellitus has not
been associated with an altered risk of thyroid cancer in
most studies [11].
In recent years, use of the antidiabetic drug metformin
has been linked to a decreased risk of some but not all
cancer types [12–15]. Furthermore, metformin showed
evidence of antitumor activity in various cancer cell lines
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[16–19] and also in thyroid cancer cell lines [20]. Pro-
posed mechanisms include reduction of mammalian tar-
get of rapamycin (mTOR) signalling by activation of
adenosine monophosphate activated protein kinase
(AMPK), and decreased insulin resistance [21]. The role
of AMPK modulation in thyroid tissue has only recently
been investigated. Abdulrahman and coworkers reported
that activation of AMPK by metformin decreased iodide
uptake by a rat follicular thyroid cell-line, while iodide
uptake was increased by compound C, an inhibitor of
AMPK [22]. Metformin decreased cancer cell growth in
various thyroid cancer cell models [20, 23], suppressed
self-renewal of cancer stem cells [23], and downregu-
lated AMPK-dependent cell signalling [20].
In contrast, Andrade et al. demonstrated that activa-
tion of AMPK increased glucose uptake in rat follicular
thyroid PCCL3 cells by upregulation of glucose trans-
porter 1 (GLUT1) [24]. It has repeatedly been shown
that GLUT1 is overexpressed in thyroid cancer cells
compared to normal thyroid tissue [25, 26] and that this
may be an indicator of thyroid cancer progression and
aggressiveness [24, 26]. Therefore, AMPK activation by
metformin could, in theory, lead to increased glucose
uptake and thyroid cancer progression. To our know-
ledge, two published observational studies have so far
explored the risk of thyroid cancer in association with
use of metformin [6, 27]. In one of these Taiwan-based
studies, Tseng [6] did not find an association between
ever use of metformin and thyroid cancer but suggested
an increased risk of thyroid cancer for users of sulfonyl-
ureas. Data from a recently published investigation by
the same author, this time using a different study design,
suggested a decreased risk of thyroid cancer in patients
with diabetes [27].
The primary aim of this study was to explore whether
use of metformin or of other antidiabetic drugs is associ-
ated with an altered risk of thyroid cancer.
Methods
Data source
Data were derived from the U.K.-based Clinical Practice
Research Datalink (CPRD), the former General Practice
Research Database (GPRD), a large primary care data-
base which was established in 1987. It encompasses data
on some 7 million individuals registered with selected
general practitioners (GPs) [28]. Patients enrolled in par-
ticipating practices are representative of the U.K. with
regard to age, sex, and geographic distribution. GPs have
been trained to record medical information including
demographic data, medical diagnoses, hospitalizations,
deaths, and drug prescriptions for research purposes
using standard software and standard coding systems.
They generate prescriptions directly with the computer,
and this information is automatically transcribed into
the computer record. The medical record contains the
name of the preparation, instructions for use, route of
administration, dose, and number of tablets for each
prescription. Additionally, the CPRD holds information
regarding lifestyle variables such as BMI, smoking, and
alcohol consumption, and information on symptoms,
medical diagnoses, referrals to consultants, and hospital-
izations. The recorded information on drug exposure
and diagnoses has repeatedly been validated and has
proven to be of high quality [29, 30]. The CPRD has
been the source of many observational studies, including
research on diabetes and on antidiabetic drugs [31, 32]
as well as on cancer [12, 33, 34]. The study was approved
by the Independent Scientific Advisory Committee (ISAC)
for the Medicines and Healthcare products Regulatory
Agency (MHRA) database research.
Study population
Case patients
We used medical READ codes [29] to identify all sub-
jects below the age of 90 years in the CPRD who had a
first-time diagnosis of thyroid cancer between January
1995 and December 2014. We excluded all patients with
less than 3 years of active history (defined as having
been actively registered and having had the opportunity
for recordings of either a diagnosis, a drug prescription,
an immunization or a lab value in the CPRD database
after January 1988) in the database prior to the date of
the thyroid cancer diagnosis (subsequently referred to as
‘index date’). Those with a history of any other cancer
(except non—melanoma skin cancer), alcoholism (i.e.
pathological alcohol consumption), or HIV infection
prior to the original index date were also excluded. We
shifted the index date for both cases and controls 2 years
backward in time for all analyses to reduce the risk of
protopathic bias where clinical symptoms of the cancer
may have led to modification of the antidiabetic drug
treatment and to ensure that exposure to antidiabetic
drugs indeed preceded the onset of cancer. Additionally,
we assessed whether cases had recorded radiotherapy
(including iodine-131 radiotherapy), chemotherapy,
thyroid surgery, or specific oncology codes, all indicators
of the validity of the cancer diagnosis.
Control patients
From the base population we identified six controls with
no diagnosis of thyroid cancer for each case at random,
matched on calendar time (same index date), age (same
year of birth), sex, general practice, and number of years
of active history on the database prior to the index date.
Therefore, the observation period for both cases and
controls was the period between the date of entry into
the CPRD and the index date. The same exclusion cri-
teria were applied to controls as to cases.
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Exposure to antidiabetic drugs, diabetes mellitus, and
diabetes duration
The exposure of interest was the use of different antidia-
betic drugs (insulin, metformin, sulfonylurea and thiazo-
lidinediones [TZD]) prior to the shifted index date for
cases and controls. In addition to analyzing the effect of
any use compared to non-use of the respective antidia-
betic drug, we defined several exposure levels based on
the recorded number of prescriptions for metformin and
sulfonylureas and classified patients into short-term
(1–29 prescriptions) or long-term (≥30 prescriptions)
users. Since exposure to TZD and insulin was rare, we
could not study different prescription categories for these
drug classes. We further assessed whether cases and con-
trols had a diagnosis of diabetes mellitus recorded prior to
the index date. We also assessed diabetes duration (cate-
gorized into the three categories <4 years, 4–8 years, and
>8 years), as well as the last recorded level of glycosylated
hemoglobin (A1C) prior to the index date.
Covariates and sensitivity analyses
In addition to diabetes mellitus we assessed the preva-
lence of various other comorbidities prior to the index
date such as hypothyroidism or hyperthyroidism, goiter,
cardiovascular diseases (congestive heart failure, ische-
mic heart disease, stroke or transient ischemic attack, ar-
terial hypertension), and dyslipidemia in cases and
controls. Additionally, we classified cases and controls
according to their smoking status (non-smoker, current,
past, unknown), alcohol consumption (none, current,
past, unknown), and BMI (<25 kg/m2, 25–29.9 kg/m2,
>30 kg/m2, unknown). Finally, we explored the associ-
ation between exposure to acetylsalicylic acid (ASA),
other non-steroidal anti-inflammatory drugs (NSAIDs),
or statins and the risk of thyroid cancer in bivariate
analyses as they have been previously associated with
an altered risk of thyroid cancer [35–37].
We conducted a sensitivity analysis in patients with
diabetes mellitus, i.e. we compared exposure to anti-
diabetic drugs between cases and controls who all
had diagnosed diabetes in order to evaluate potential
confounding by indication. For this analysis, we iden-
tified additional controls with a diabetes diagnosis
(but without a cancer diagnosis) from the database in
order to a match one diabetic cancer case to six diabetic
controls. We also assessed the influence of diabetes
duration and A1C as potential confounders. Since
A1C did not materially change our findings in bivari-
ate analyses, we did not include it in the multivariate
sensitivity analysis.
Statistical analysis
We conducted conditional logistic regression analyses
using the SAS statistical software version 9.4 (SAS
Institute Inc, Cary, NC) to calculate relative risk esti-
mates of insulin use or oral antidiabetic drug use among
cases with thyroid cancer, compared with controls with-
out thyroid cancer, expressed as odds ratios (ORs) with
95 % confidence intervals (CIs). We a priori adjusted for
the potential confounders BMI, smoking, and a recorded
diagnosis of diabetes mellitus (or diabetes duration in
the sensitivity analysis restricted to diabetic cases and
controls) in the multivariate model. We also explored
the crude association between predefined covariates as
discussed above and the risk of thyroid cancer. More-
over, we assessed the effect of these covariates on the
relative risk estimate by including them one by one in
our a priori model. Since hyperthyroidism and goiter are
also known risk factors for thyroid cancer and they
yielded high OR in our univariate analyses, we decided
to present a second multivariate model including those
two variables.
Results
We identified 1229 cases with an incident diagnosis
of thyroid cancer and 7374 matched controls. Mean
(± standard deviation [SD]) age at diagnosis was 51.4 ±
17.7 years, and 74.5 % of cases were female. Mean (± SD)
recorded history in the database prior to the diagnosis
date was 4035 ± 1838 days for cases and 4040 ± 1827 days
for controls. Table 1 displays detailed demographic data of
cases and controls. Eighty-eight percent of cases had re-
corded codes for oncologic evaluation, thyroid surgery,
radio- or chemotherapy within 6 months before or after
the diagnosis date.
BMI and cardiovascular comorbidities (including dys-
lipidemia) were not associated with an altered risk of
thyroid cancer (Table 1). Current smoking status (OR
0.66, 95 % CI 0.55–0.79) and current alcohol consump-
tion (OR 0.81, 95 % CI 0.69–0.96) were associated with
a decreased risk, while hyperthyroidism (OR 2.29, 95 %
CI 1.54–3.42) and goiter (OR 10.60, 95 % CI 7.62–14.74)
were associated with increased risks of thyroid cancer.
Use of ASA, NSAIDs, and statins had no effect on the
risk of thyroid cancer, nor did diabetes mellitus or pro-
longed diabetes duration (Table 1).
Any prior use of metformin yielded an adjusted OR of
1.48 for the risk of thyroid cancer in the main model
and of 1.30 in the sensitivity analysis restricted to dia-
betic cases and controls, although the results were not
statistically significant (Tables 2 and 3). When we stratified
our analyses according to exposure duration, we observed
a higher risk in both models for long-term metformin use
(≥30 prescriptions) compared to non-use, with adjusted
ORs of 1.83 (95 % CI 0.92–3.65) in the main model, and
1.48 (95 % CI 0.69–3.18) in the sensitivity analysis re-
stricted to diabetic patients (Tables 2 and 3). To address
potential bias of exposure time opportunity (time window
Becker et al. BMC Cancer  (2015) 15:719 Page 3 of 9
Table 1 Characteristics of patients with thyroid cancer and their controls
Cases (%) (n = 1229) Controls (%) (n = 7374) Crude OR (95 % CI)
Age (years) <40 335 (27.3) 2010 (27.3) -
40–59 455 (37.0) 2745 (37.2) -
60–69 206 (16.8) 1200 (16.3) -
70–79 174 (14.2) 1064 (14.4) -
≥80 59 (4.8) 355 (4.8) -
Sex Male 314 (25.6) 1884 (25.6) -
Female 915 (74.5) 5490 (74.5) -
BMI <25 435 (35.4) 2717 (36.9) 1.00 (referent)
25–29.9 337 (27.4) 1977 (26.8) 1.07 (0.92–1.26)
30–59.9 245 (19.9) 1222 (16.6) 1.27 (1.07–1.51)
Unknown 212 (17.3) 1458 (19.8) 0.85 (0.69–1.04)
Smoking Non-smoker 693 (56.4) 3603 (48.9) 1.00 (referent)
Current 182 (14.8) 1406 (19.1) 0.66 (0.55–0.79)
Past 235 (19.1) 1560 (21.2) 0.78 (0.66–0.92)
Unknown 119 (9.7) 805 (10.9) 0.72 (0.55–0.92)
Alcohol consumption None 244 (19.9) 1233 (16.7) 1.00 (referent)
Current 819 (66.6) 4989 (67.7) 0.81 (0.69–0.96)
Past 13 (1.1) 74 (1.0) 0.88 (0.48–1.62)
Unknown 153 (12.5) 1078 (14.6) 0.67 (0.52–0.85)
Hypothyroidism No 1157 (94.1) 7022 (95.2) 1.00 (referent)
Yes 72 (5.9) 352 (4.8) 1.25 (0.96–1.63)
Hyperthyroidism No 1195 (97.2) 7284 (98.8) 1.00 (referent)
Yes 34 (2.8) 90 (1.2) 2.29 (1.54–3.42)
Goitera No 1129 (91.9) 7313 (99.2) 1.00 (referent)
Yes 100 (8.1) 61 (0.8) 10.60 (7.62–14.74)
Diabetes mellitus No 1159 (94.3) 7009 (95.1) 1.00 (referent)
Yes 70 (5.7) 365 (5.0) 1.17 (0.89–1.54)
DM durationb < 4 ys. 24 (34.3) 142 (33.9) 1.00 (referent)
DM durationb 4–8 ys. 18 (25.7) 133 (31.7) 0.71 (0.32–1.60)
DM durationb > 8 ys. 28 (40.0) 144 (34.4) 1.22 (0.60–2.51)
A1c <53 mmol/l (7 %) 32 (45.7) 175 (41.8) 1.00 (referent)
A1c≥ 53 mmol/l (7 %) 32 (45.7) 217 (51.8) 0.80 (0.46–1.38)
Unknown A1c level 6 (8.6) 27 (6.4) 1.24 (0.44–3.48)
CHF No 1217 (99.0) 7283 (98.8) 1.00 (referent)
Yes 12 (1.0) 91 (1.2) 0.78 (0.42–1.45)
IHD No 1160 (94.4) 6934 (94.0) 1.00 (referent)
Yes 69 (5.6) 440 (6.0) 0.93 (0.70–1.23)
Hypertension No 968 (78.8) 5918 (80.3) 1.00 (referent)
Yes 261 (21.2) 1456 (19.8) 1.13 (0.95–1.34)
Stroke/TIA No 1198 (97.5) 7147 (96.9) 1.00 (referent)
Yes 31 (2.5) 227 (3.1) 0.81 (0.55–1.19)
Dyslipidemia No 1144 (93.1) 6800 (92.2) 1.00 (referent)
Yes 85 (6.9) 574 (7.8) 0.86 (0.67–1.11)
NSAID No prior use 518 (42.2) 3083 (41.8) 1.00 (referent)
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bias), we explored whether cases with long-term metfor-
min use (≥30 prescriptions) had longer duration of dia-
betes mellitus than controls and therefore a higher
probability of receiving a prescription. Among all cancer
cases with long-term metformin use, 81 % had diabetes
duration of more than 4 years and 58 % of more than
8 years. Among controls, 95 % had diabetes duration of
more than 4 years and 56 % of more than 8 years.
Any use of sulfonylureas was associated with a non-
significant increased risk of thyroid cancer in both
models (Tables 2 and 3), and did not increase with long-
term use (≥30 prescriptions: adjusted OR 1.25, 95 % CI
0.62–2.54). Exposure to insulin or TZD was low and did
not produce significant results.
Discussion
The results of this observational study did not show a
decreased risk of thyroid cancer in association with the
use of metformin. In the relatively small number of pa-
tients with long-term metformin exposure, there was
some suggestion of a possible association between met-
formin and thyroid cancer, although this finding was not
statistically significant.
The OR was higher in long-term users of metformin,
suggesting (but not proving) a possible association
between metformin and thyroid cancer. However, confi-
dence intervals varied considerably due to limited statis-
tical power, and our findings need to be confirmed in
other large observational studies. No statistically
Table 1 Characteristics of patients with thyroid cancer and their controls (Continued)
1–4 Rx. 447 (36.4) 2740 (37.2) 0.97 (0.84–1.12)
≥5 Rx. 264 (21.5) 1551 (21.0) 1.02 (0.85–1.21)
ASA No prior use 1065 (86.7) 6365 (86.3) 1.00 (referent)
1–14 Rx. 78 (6.4) 481 (6.5) 0.96 (0.75–1.25)
≥15 Rx. 86 (7.0) 528 (7.2) 0.96 (0.74–1.26)
Statins No prior use 1078 (87.7) 6453 (87.5) 1.00 (referent)
1–14 Rx. 47 (3.8) 337 (4.6) 0.83 (0.60–1.15)
≥15 Rx. 104 (8.5) 584 (7.9) 1.07 (0.83–1.38)
A1c = glycated hemoglobin, assessed for diabetics only, ‘unknown’ level includes recordings earlier than 1 year before the cancer diagnosis
OR odds ratio, CI confidence interval, BMI body mass index, CHF congestive heart failure, IHD ischemic heart disease, TIA transient ischemic attack, NSAID non-steroidal
anti-inflammatory drugs, ASA acetylsalicylic acid
aGoiter includes toxic and nontoxic forms
bAnalysis restricted to cases and controls with a recorded diagnosis of diabetes mellitus
Table 2 Use of antidiabetic drugs and the risk of thyroid cancer
Drugs and No. prescriptions Cases (%) (n = 1229) Controls (%) (n = 7374) Crude OR (95 % CI) Adjusted OR
(95 % CI) model 1a
Adjusted OR
(95 % CI) model 2b
Metformin
No prior use 1180 (96.0) 7166 (97.2) 1.00 (referent) 1.00 (referent) 1.00 (referent)
Any use 49 (4.0) 208 (2.8) 1.46 (1.05–2.02) 1.48 (0.86–2.54) 1.56 (0.90–2.71)
1–29 23 (1.9) 116 (1.6) 1.23 (0.78–1.94) 1.31 (0.71–2.40) 1.34 (0.72–2.48)
≥30 26 (2.1) 92 (1.3) 1.75 (1.12–2.72) 1.83 (0.92–3.65) 2.07 (1.03–4.18)
Sulfonylurea
No prior use 1191 (96.9) 7220 (97.9) 1.00 (referent) 1.00 (referent) 1.00 (referent)
Any use 38 (3.1) 154 (2.1) 1.52 (1.05–2.20) 1.42 (0.82–2.46) 1.41 (0.81–2.48)
1–29 19 (1.6) 77 (1.0) 1.51 (0.91–2.51) 1.45 (0.76–2.77) 1.42 (0.73–2.76)
≥30 19 (1.6) 77 (1.0) 1.54 (0.91–2.59) 1.25 (0.62–2.54) 1.23 (0.60–2.53)
Insulin
No prior use 1211 (98.5) 7287 (98.8) 1.00 (referent) 1.00 (referent) 1.00 (referent)
Any use 18 (1.5) 87 (1.2) 1.25 (0.75–2.10) 1.14 (0.62–2.09) 1.14 (0.62–2.12)
TZD
No prior use 1220 (99.3) 7333 (99.4) 1.00 (referent) 1.00 (referent) 1.00 (referent)
Any use 9 (0.7) 41 (0.6) 1.32 (0.64–2.72) 0.82 (0.36–1.84) 0.78 (0.34–1.80)
OR odds ratio, CI confidence interval
aModel 1 adjusted for all antidiabetic drugs in the table, BMI, smoking, and diabetes mellitus
bModel 2 adjusted for all antidiabetic drugs in the table, BMI, smoking, diabetes mellitus, hyperthyroidism, and goiter
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significantly altered cancer risk was observed in users of
sulfonylureas or other antidiabetic drugs. To our know-
ledge, there have been only two epidemiological investiga-
tions published to date exploring the risk of thyroid
cancer in association with antidiabetic drug treatment.
The author of these studies used a population-based reim-
bursement database in Taiwan [6, 27]. The findings from
the first analysis suggested that use of metformin (based
on 37 exposed and 906 non-exposed cancer patients) was
not associated with a statistically significantly altered risk
of thyroid cancer (adjusted OR 0.70, 95 % CI 0.42–1.16).
No data were reported on the effect of exposure duration
on the risk of thyroid cancer in this study. Similar to our
(statistically non-significant) findings, any use of sulfonyl-
ureas (based on 52 exposed and 891 non-exposed cancer
patients) was associated with an increased risk of thyroid
cancer (adjusted OR 1.88, 95 % CI 1.20–2.95), again
with no data on exposure duration. In a subsequent
cohort study, Tseng reported a markedly decreased
risk of thyroid cancer in association with ever use of
metformin (model I, HR 0.683, 95 % CI 0.598–0.780),
and a trend towards a lower risk associated with
long-term metformin use [27]. However, possible limi-
tations in the study design in the second study are,
among others, insufficient assessment of exposure
time to metformin, and the assignment of an arbitrary
artificial study entry date.
Our results are somewhat surprising given that grow-
ing available evidence suggests a possible antitumor ef-
fect of metformin or other AMPK activators in thyroid
cancer cell lines [38, 39]. However, activation of AMPK
has also been associated with increased GLUT1 expres-
sion in a rat model of thyroid cells, and increased glu-
cose uptake in thyroid cancer cells has been linked to
thyroid cancer progression and aggressiveness [24–26].
In addition, it has recently been demonstrated that
AMPK is upregulated in human papillary thyroid can-
cers [40]. On the other hand, the authors of a retrospect-
ive analysis of patients with type 2 diabetes mellitus and
differentiated thyroid cancer reported a higher remission
rate in users of metformin compared to non-users [41],
however, the definition of metformin exposure was not
reported in detail in this study. Thus, the association
between metformin use and thyroid cancer needs to
be further elucidated.
Consistent with the findings by Tseng [6], we also ob-
served a possible decreased risk of thyroid cancer in pa-
tients exposed to TZD, however, this finding was not
statistically significant and was based on a small number
of exposed cases and controls in both studies. It has
been shown in an in vivo study that TZD reduce serum
DPP-4 activity as a result of reduced DPP-4 secretion
and that DDP-4 is expressed in differentiated thyroid
cancer cells but not in normal human thyrocytes [42].
Table 3 Use of antidiabetic drugs and the risk of thyroid cancer restricted to cases and controls with a recorded diagnosis of
diabetes mellitus
Drugs and No. prescriptions Cases (%) (n = 70) Controls (%) (n = 419) Crude OR (95 % CI) Adjusted OR
(95 % CI) model 1a
Adjusted OR
(95 % CI) model 2b
Metformin
No prior use 23 (32.9) 165 (39.4) 1.00 (referent) 1.00 (referent) 1.00 (referent)
Any use 47 (67.1) 254 (60.6) 1.40 (0.78–2.49) 1.30 (0.68–2.47) 1.42 (0.74–2.73)
1–29 21 (30.0) 129 (30.8) 1.21 (0.61–2.39) 1.18 (0.57–2.45) 1.28 (0.61–2.67)
≥30 26 (37.1) 125 (29.8) 1.60 (0.83–3.09) 1.48 (0.69–3.18) 1.67 (0.76–3.67)
Sulfonylurea
No prior use 32 (45.7) 231 (55.1) 1.00 (referent) 1.00 (referent) 1.00 (referent)
Any use 38 (54.3) 188 (44.9) 1.48 (0.88–2.48) 1.51 (0.83–2.75) 1.46 (0.78–2.72)
1–29 19 (27.1) 97 (23.2) 1.43 (0.76–2.67) 1.56 (0.79–3.10) 1.52 (0.76–3.07)
≥30 19 (27.1) 91 (21.7) 1.53 (0.81–2.89) 1.41 (0.68–2.94) 1.35 (0.62–2.90)
Insulin
No prior use 52 (74.3) 349 (83.3) 1.00 (referent) 1.00 (referent) 1.00 (referent)
Any use 18 (25.7) 70 (16.7) 1.83 (0.98–3.42) 1.94 (0.97–3.88) 1.84 (0.90–3.76)
TZD
No prior use 61 (87.1) 366 (87.4) 1.00 (referent) 1.00 (referent) 1.00 (referent)
Any use 9 (12.9) 53 (12.7) 1.03 (0.45–2.33) 0.80 (0.33–1.92) 0.66 (0.26–2.90)
OR odds ratio, CI confidence interval
aModel 1 adjusted for all antidiabetic drugs in the table, BMI, smoking, and diabetes duration
bModel 2 adjusted for all antidiabetic drugs in the table, BMI, smoking, diabetes duration, hyperthyroidism, and goiter
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Further studies are needed to evaluate the role of TZD
in patients with thyroid cancer.
In our study, we additionally explored the association
between various covariates and development of thyroid
cancer. We did not find an increased risk of thyroid can-
cer in obese patients. In line with other investigations
[9], we also found a decreased risk of thyroid cancer in
association with current smoking and current alcohol
consumption. We did not find evidence for an increased
risk of thyroid cancer in patients with diabetes mellitus
compared to non-diabetic patients, regardless of diabetes
duration. Similar results have been reported by Shih and
colleagues in a recent literature review [11] and by Tseng
[6]. Benign thyroid disease, namely goiter, and to a lesser
extent hyperthyroidism were associated with increased
risks of thyroid cancer in our study, and similar findings
have been reported by other authors [6–8]. This result
may be partially explained by misclassification of benign
thyroid disease as thyroid cancer. Other explanations
may be that frequent check-ups of benign thyroid le-
sions increased the likelihood for detecting thyroid can-
cer, or that lesions initially judged to be benign turned
out to be malignant in follow-up investigations. Of note,
inclusion of goiter and hyperthyroidism in another sensi-
tivity analysis (model 2) did not materially change the
association between antidiabetic drug use and the risk of
thyroid cancer.
Recently, use of statins and NSAIDs have been re-
ported to be associated with markedly decreased risks of
thyroid cancer of 45 and 90 %, respectively [6]. We did
not find such associations, nor did we find decreased
risks with increasing duration of use (Table 1). Despite
some encouraging results from mechanistic studies
using rosuvastatin [43] and lovastatin [44, 45], our re-
sults do not support an overall beneficial effect of statins
in preventing thyroid cancer.
There are several limitations in this study. First, the re-
sults are based on a limited number of cases and con-
trols despite using a large electronic health records
database. Therefore, more data is needed to confirm our
findings. Second, we may have missed some thyroid can-
cer cases, and misclassification of benign thyroid lesions
as thyroid cancer cannot be ruled out. However, such
misclassification would most likely be equally distributed
among different antidiabetic drug groups and would
therefore introduce a bias towards the null, and not ex-
plain the increased risk found in metformin users. In
addition, 88 % of cases had a recorded code for cancer-
specific therapeutic interventions after the index date,
which makes substantial misclassification unlikely. Fi-
nally, in the CPRD cancer diagnoses are recorded with
high validity and reasonably high agreement with linked
cancer registries [46]. Third, despite assessing the role of
numerous potential confounders of the association
between thyroid cancer and antidiabetic drug use, we
cannot exclude residual confounding by unknown vari-
ables. However, conditions known to be risk factors for
thyroid cancer for which no detailed information was
available in the CPRD (e.g. exposure to radiation in
childhood, or a history of a familial thyroid cancer syn-
drome) should not confound the association of interest
since they are not likely linked with exposure to a par-
ticular antidiabetic drug class. Fourth, our results are
most likely only representative of papillary thyroid can-
cer, because this type accounts for most thyroid cancers
[2]. However, we were not in the position to determine
the histological subtype of the cancer cases, so it is pos-
sible that metformin exposure does not similarly affect
the development of other thyroid cancer cells. Fifth,
since higher socioeconomic status (SES) is a surrogate
for access to diagnostic procedures and has been associ-
ated with increased detection of thyroid cancer [3], SES
may also be related to antidiabetic drug use, so we can-
not fully exclude confounding by SES. However, we
matched cases and controls on general practice and at
least partially controlled for SES, since patients from the
same neighborhood tend to attend the same general
practice.
Our study also has several strengths. We used the
CPRD, a longitudinal, well-established, and repeatedly
validated primary care database designed for research
purposes. In addition to the main analysis we ran a sen-
sitivity analysis in diabetic cases and controls which
yielded closely similar findings. We carefully assessed
the role of potential confounders on the association of
interest. Furthermore, by shifting the original index date
2 years back in time we increased the likelihood that
antidiabetic drug exposure preceded cancer develop-
ment, and we minimized the risk that clinical manifes-
tations of evolving cancer led to changes in antidiabetic
drug treatment in cases. Additionally, by excluding all
patients with less than 3 years of active history prior to
the index date, we reduced the risk of including preva-
lent rather than incident cancer cases. Finally, time-
related biases are most likely not an issue in this study;
immortal time bias is ruled out because of risk-set sam-
pling of cases and controls, and bias due to different
time of exposure opportunity (time window bias) is also
not present.
Conclusion
Neither use of metformin nor of any other anti-diabetes
medication was statistically significantly associated with
an altered relative thyroid cancer risk in this population-
based observational study.
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